Cyclosporine ophthalmic

Cyclosporine ophthalmic emulsion One drop in each eye twice... 

Sail, K., et al. 2000. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group. Ophthalmology 107 631. 

Ding, S., and Olejnik, O. (1997), Cyclosporin ophthalmic oil/water emulsions. Formulation and characterization, Pharm. Res., 14, S41. 

Turner, K., Pflugfelder, S. C., Ji, Z., Feuer, W. J., Stern, M., and Reis, B. L. (2000), Interleukin-6 levels in the conjunctival epithelium of patients with dry eye disease treated with cyclosporine ophthalmic emulsion, Cornea, 19, 492—496. 

Kunert KS, Tisdale AS, Stern ME. Effect of cyclosporine ophthalmic emulsion on the number of inflammatory cells and goblet cells in conjunctival biopsies with dry eye. Invest Ophthalmol Vis Sci 1999 44(suppl) S771. 

Tauber JT. A dose-ranging clinical trial to assess the safety and efficacy of cyclosporine ophthalmic emulsion in patients with keratoconjunctivitis sicca. In Sullivan DA, Dartt DA, Meneray MA, eds. Lacrimal gland, tear film, and dry eye syndromes 2 basic science and clinical relevance. New York Plenum Press, 1998 693-704. 

Dry eye affects about 4.9 million people aged fifty and older in the United States. It may seem like a minor eye condition, but dry eye results in discomfort, changes in vision, tear film instability, and serious damage to the surface of the eye. Treatments for dry eye used to be limited to continued use of artificial tear products or surgical blockage of a tear duct in the eye, which decreased the amount of tears that could drain from the eye. In 2002, the FDA approved cyclosporine ophthalmic solution (Restasis),... 

Cyclosporine A Restasis Allergan Ophthalmic Immunomodulator Marketed in UnitStetes Physicians Desk Reference, p. 556 (2004)... 

Stevenson, D., J. Tauber, and B.L. Reis. 2000. Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease A dose-ranging, randomized trial. The Cyclosporin A Phase 2 Study Group. Ophthalmology 107 967. 

Small, D. S., Acheampong, A., Reis, B., Stern, K., Stewart, W., Berdy, G., Epstein, R., Foerster, R., Forstot, L., and Tang-Liu, D. D.-S. (2002), Blood concentrations of cyclosporin A during long-term treatment with cyclosporin A ophthalmic emulsions in patients with moderate to severe dry eye disease, J. Ocul. Pharmacol. Then, 18, 411 118. 

Horn, M. M. (2006), Use of cyclosporine 0.05% ophthalmic emulsion for contact lens-intolerant patients, Eye Contact Lens Sci. Clin. Pract., 32,109-111. 

Barber LD, Pflugfelder SC, Tauber J, et al. Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years. Ophthalmology 2005 112 1790-1794. 

Laibovitz RA, Solch S, Andriano K, et al. Pilot trial of cyclosporine 1% ophthalmic ointment in the treatment of keratoconjunctivitis sicca. Cornea 1993 12 315-323. 

---